MarketCap
Facebook
X
Telegram
Baxter International Cash Flow 2025-2011 | BAX
Brief overview of Baxter International 's cash generation
The comparison covers five available annual reports between 2021 and 2025.
Cash from operations fell 62%, from $2.2 billion to $845 million. The direction warrants attention.
Operating cash flow stayed positive in five out of five periods. The business consistently converted operations into cash.
Operating cash margin decreased to 7.5% from 18.3% initially. The quality of receipts deteriorated.
A $674 million reduction in working capital needs released cash equal to 6% of revenue.
Overall assessment
Baxter International 's cash flows present a mixed picture: positive periods coexist with weak conversion or high funding needs.
Annual Cash Flow Baxter International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
845 M | 1.02 B | 1.73 B | 1.21 B | 2.22 B | 1.87 B | 2.1 B | 2.02 B | 1.71 B | 1.65 B | 1.77 B | 3.22 B | 3.2 B | 3.11 B | 2.82 B |
Depreciation & Amortization |
981 M | 997 M | 984 M | 1.07 B | 867 M | 823 M | 789 M | 771 M | 750 M | 800 M | 759 M | 792 M | 635 M | 712 M | 670 M |
Accounts Payables |
999 M | 968 M | 881 M | 1.11 B | 1.25 B | 1.04 B | 892 M | 1 B | 920 M | 791 M | 716 M | 1.26 B | 1.1 B | 766 M | 795 M |
Accounts Receivables |
1.7 B | 1.54 B | 1.54 B | 2.34 B | 2.4 B | 1.7 B | 1.8 B | 1.7 B | 1.79 B | 1.69 B | 1.73 B | 2.8 B | 2.91 B | 2.42 B | 2.42 B |
Total Inventories |
2.23 B | 2.05 B | 1.92 B | 2.68 B | 2.45 B | 1.92 B | 1.65 B | 1.65 B | 1.48 B | 1.43 B | 1.6 B | 3.56 B | 3.5 B | 2.8 B | 2.63 B |
All numbers in USD currency
Quarterly Cash Flow Baxter International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
213 M | - | - | -193 M | - | - | 163 M | - | - | 479 M | - | 772 M | - | 208 M | - | 1.53 B | - | 377 M | - | 1.16 B | 646 M | 272 M | - | 1.28 B | 574 M | 128 M | - | 1.31 B | 852 M | 430 M | - | 1.32 B | 718 M | 189 M | - | 941 M | 409 M | -333 M | - | 1.05 B | 792 M | 96 M | - | 2.07 B | 1.16 B | 559 M | - | 2.12 B | 1.15 B | 386 M | - | 2.16 B | 1.41 B | 446 M | - | 1.92 B | 1 B | 371 M |
Depreciation & Amortization |
237 M | 90 M | 106 M | 247 M | 95 M | 73 M | 271 M | 147 M | 157 M | 313 M | - | 168 M | 193 M | 380 M | - | 645 M | 67 M | 217 M | - | 610 M | 401 M | 199 M | - | 580 M | 385 M | 192 M | - | 586 M | 387 M | 190 M | - | 562 M | 378 M | 194 M | - | 599 M | 395 M | 189 M | - | 593 M | 377 M | 187 M | - | 592 M | 489 M | 236 M | - | 573 M | 366 M | 183 M | - | 534 M | 355 M | 175 M | - | 503 M | 327 M | 158 M |
Accounts Payables |
1.09 B | 953 M | 995 M | 963 M | 841 M | 1.25 B | 1.33 B | 1.25 B | 1.24 B | 1.29 B | 1.11 B | 1.23 B | - | 1.22 B | 1.25 B | 999 M | 1 B | 1.02 B | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 892 M | - | - | - | 998 M | - | - | - | 920 M | - | - | - | 791 M | - | - | - | 716 M | - | - | - | 677 M | - | - | - | 1.1 B | - | - | - | 766 M | - | - | - | 795 M | - | - | - |
Accounts Receivables |
1.54 B | 1.64 B | 1.62 B | 1.49 B | 1.54 B | 2.37 B | 2.26 B | 2.28 B | 2.27 B | 2.3 B | 2.34 B | 2.3 B | - | 2.3 B | 2.4 B | 1.8 B | 1.8 B | 1.6 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.69 B | 1.69 B | 1.69 B | 1.69 B | 1.73 B | 1.73 B | 1.73 B | 1.73 B | 1.88 B | 1.88 B | 2.8 B | 2.8 B | 2.91 B | 2.91 B | 2.91 B | 2.91 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.35 B | 2.49 B | 2.4 B |
Total Inventories |
2.32 B | 2.46 B | 2.38 B | 2.17 B | 2.1 B | 2.98 B | 2.99 B | 2.87 B | 2.9 B | 2.92 B | 2.68 B | 2.68 B | - | 2.55 B | 2.45 B | 2.02 B | 2.06 B | 2.02 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.65 B | 1.65 B | 1.65 B | 1.65 B | 1.67 B | 1.67 B | 1.65 B | 1.65 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 1.43 B | 1.43 B | 1.43 B | 1.43 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.58 B | 1.58 B | 3.56 B | 3.56 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.63 B | 2.63 B | 2.63 B | 2.63 B |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Baxter International , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Merit Medical Systems
MMSI
|
$ 80.84 | 3.26 % | $ 4.78 B |  USA |
 |
Repligen Corporation
RGEN
|
$ 141.23 | -2.83 % | $ 7.94 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
BioLife Solutions
BLFS
|
$ 31.5 | -1.5 % | $ 1.5 B | USA |
 |
electroCore
ECOR
|
$ 6.07 | -0.33 % | $ 51.5 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Nephros
NEPH
|
$ 3.24 | -7.43 % | $ 34.4 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
AtriCure
ATRC
|
$ 40.89 | 2.87 % | $ 1.95 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 337.46 | 0.2 % | $ 24.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 14.2 | 5.26 % | $ 2.83 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 85.42 | 3.49 % | $ 4.03 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
The Cooper Companies
COO
|
$ 73.06 | 1.39 % | $ 14.5 B | USA |
 |
AngioDynamics
ANGO
|
$ 14.63 | 2.02 % | $ 608 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 122.44 | 4.32 % | $ 3.92 B | USA |
 |
Pro-Dex
PDEX
|
$ 54.88 | -2.59 % | $ 180 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.76 | -1.61 % | $ 202 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 161.66 | 6.83 % | $ 9.25 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.12 | 3.38 % | $ 272 M | USA |
 |
ICU Medical
ICUI
|
$ 166.53 | 0.46 % | $ 4.1 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 353.1 | -2.4 % | $ 126 B | USA |
 |
Alcon
ALC
|
$ 69.65 | 0.75 % | $ 40.4 B |  Schweiz |
 |
Pulse Biosciences
PLSE
|
$ 34.25 | -3.44 % | $ 2.31 B | USA |
 |
STERIS plc
STE
|
$ 234.83 | 1.95 % | $ 23.1 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.38 | -12.56 % | $ 31.2 M | USA |
 |
ResMed
RMD
|
$ 214.29 | 2.55 % | $ 31.4 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 28.37 | 5.23 % | $ 4.77 B | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.67 | -0.6 % | $ 76.5 M |  Israel |
 |
STAAR Surgical Company
STAA
|
$ 23.87 | 5.34 % | $ 1.18 B | USA |
 |
Stereotaxis
STXS
|
$ 1.33 | 3.91 % | $ 121 M | USA |
 |
Repro Med Systems
KRMD
|
$ 4.07 | 1.5 % | $ 188 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.97 | -1.24 % | $ 292 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 134.65 | 0.34 % | $ 6.01 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 103.57 | 1.24 % | $ 2.34 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 168.4 | 1.24 % | $ 48.4 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.67 | 0.01 % | $ 20.1 M | USA |
 |
Utah Medical Products
UTMD
|
$ 70.94 | -0.03 % | $ 230 M | USA |